Claim this global strategic report to understand unique product opportunities by stem cell type, derive more revenue from products sold to stem cell scientists, and identify new product development opportunities before the competition. Use the “Survey of Stem Cell Scientists” to understand technical requirements, unmet needs, and purchasing preferences of stem cell researchers worldwide.
This report explores unique market opportunities by stem cell type, including mesenchymal stem cells, hematopoietic stem cells, induced pluripotent stem cells, embryonic stem cells, neural stem cells, and more.
The Market for Stem Cell Research Products
Stem cells are primitive cells found in all multi-cellular organisms that are characterized by self-renewal and the capacity to differentiate into any mature cell type. Several broad categories of stem cells exist, including:
- Embryonic stem cells, derived from blastocysts
- Perinatal stem cells, obtained during the period immediately before and after birth
- Adult stem cells, found in adult tissues
- Induced pluripotent stem cells, produced by genetically reprogramming adults cells
- Cancer stem cells, which give rise to clonal populations of cells that form tumors or disperse in the body
Stem cell research and experimentation have been in process for well over five decades, as stem cells have the unique ability to divide and replicate repeatedly. In addition, their “unspecialized” nature allows them to differentiate into a wide variety of specialized cell types.
In a developing embryo, stem cells can differentiate into all of the specialized embryonic tissues. In adult organisms, stem and progenitor cells act as a repair system for the body, replenishing specialized cells.
Traditionally, scientists have worked with both embryonic and adult stem cells as research tools. While the appeal of embryonic cells has been their ability to differentiate into any type of cell, there has been significant ethical, moral and spiritual controversy surrounding their use for research purposes. Although some adult stem cells do have differentiation capacity, it is often limited in nature, which results in fewer options for use.
Thus, when induced pluripotent stem cells (iPSCs) were produced from mouse cells in 2006 by Shinya Yamanaka of Kyoto University in Japan, they represented a promising combination of adult and embryonic stem cell characteristics. By 2007, a series of follow-up experiments were done at Kyoto University in which human adult cells were transformed into iPSC cells. Nearly simultaneously, a research group led by James Thomson at the University of Wisconsin-Madison accomplished the same feat of deriving iPSC lines from human somatic cells.
The possibilities arising from these characteristics have resulted in great commercial interest, with potential applications ranging from the use of stem cells in reversal and treatment of disease, to targeted cell therapy, tissue regeneration, pharmacological testing on cell-specific tissues, and more. Huntington’s disease, Parkinson’s disease, and spinal cord injuries are examples of conditions for which clinical applications involving stem cells could offer benefits in halting or even reversing adverse effects.
Also of interest to clinical researchers is the potential to use stem cells in regenerative medicine. Additionally, the ability to use stem cells to improve drug target validation and toxicology screening is of intense interest to the pharmaceutical industry.
At this time, the following account for the majority of stem cell research:
- Basic Research – Understanding stem cell mechanisms and behavior
- Regenerative Medicine – Reversal of injury or disease
- Drug Target Validation and Drug Delivery – Treatment of disease
- Toxicology Screening – Drug safety and efficacy assessment
To facilitate research resulting from interest in these potential far-ranging applications, a large and growing stem cells research products market has emerged.
Large companies selling stem cell research products include:
- Thermo Fisher Scientific
- BD Biosciences, a Division of Becton Dickinson
- Merck KGaA
- Miltenyi Biotec
- STEMCELL Technologies
- Lonza Group
- Clontech (a Takara Bio Company)
- GE Healthcare Life Sciences.
While several of these dominant market players have utilized acquisition strategies to grow and capture market share, Merck KGaA has had a particularly strong commitment to this approach, acquiring several other massive major players within the stem cell research products marketplace, including Milllipore on February 26, 2010, for $7.2 billion, and Sigma-Aldrich on September 22, 2014, for $17 billion. Dozens of mid-sized suppliers of stem cell research products also exist, as well as over 100 small specialty providers.
Currently, the following compose the majority of stem cell research product sales worldwide:
- Primary antibodies to stem cell antigens
- Bead-based stem cell separation systems
- Fluorescent-based labeling and detection
- Stem cell protein purification and analysis tools
- Tools for DNA and RNA-based characterization of stem cells
- Isolation/characterization services
- Stem cell culture media and reagents
- Stem cell specific growth factors and cytokines
- Tools for stem cell gene regulation
- Stem cell services and mechanisms for in vivo and in vitro stem cell tracking
- Expansion/differentiation services for stem cell media and RNAi
- Stem cell lines
Currently, mesenchymal stem cells (MSCs) are one of the fastest growing areas of stem cell research, with more than 25,000 scientific publications published about the cell type and more than 400 clinical trials underway worldwide. Importantly, 2015 was the first year in history that mesenchymal stem cells surpassed hematopoietic stem cells (HSCs) for the most scientific publications of any stem cell type. In addition, Google Trend data shows MSC searches to be approximately twice as common as the next most popular stem cell type.
MSCs also being explored for use in 3D printing applications, because of their unique capacity to form structural tissues. In particular, there will be a demand for companies to supply MSC populations for use in 3D printing inks.
Induced pluripotent stem cells (iPSCs) are also an interesting area of stem cell research, with Japan committing to being a market leader in this area. In the past year, Japan has accelerated its position as a hub for regenerative medicine research, largely driven by support from Prime Minister Shinzo Abe who has identified regenerative medicine and cellular therapy as key to the Japan’s strategy to drive economic growth.
The Prime Minister has encouraged a growing range of collaborations between private industry and academic partners through an innovative legal framework. Most importantly to the stem cell research products marketplace, Japan’s Education Ministry said it is planning to spend 110 billion yen ($1.13 billion) on induced pluripotent stem cell research during the next 10 years, and the Japanese parliament has been discussing bills that would “speed the approval process and ensure the safety of such treatments.”
Utilization of other stem cell types in research settings continue as well, with hematopoietic stem cells being explored for their broad therapeutic applications, neural stem cells being explored for their ability to address unmet medical needs, and adipose-derived stem cells catching the interest of the research community because of the increasing prevalence of orthopedic doctors who are using these cells for musculoskelal applications, an area that the FDA has begun to tightly regulate.
Key report findings include:
- Market size determinations, with 5-year projections for the stem cell research products market (2016-2020)
- Year-over-year analysis of stem cell grant rates, patent rates, clinical trial rates, and scientific publication rates
- Stem cell funding sources, trends, and amounts (domestic and international)
- Stem cell research applications, including priorities by segment
- Relative demand for stem cell products, by stem cell type
- Breakdown of stem cell product categories
- Competitive analysis of leading stem cell research product companies
- Online trends for stem cells, including Google Trends and Google Adwords
- Social analytics for stem cells, including activity on Twitter, LinkedIn, Facebook, and more
- Communications strategies for accessing the marketplace
- End-user survey of stem cell scientists
Competing within the stem cell marketplace can involve complicated and confusing decisions, but it doesn’t have to. Claim this report to reveal the current and future needs of your customer base, so you can focus your marketing efforts on profitable products, in promising research areas, within lucrative markets.
The content and statistics contained in this report were compiled using a broad range of sources. These input sources include:
- Stem Cell Grant Funding Database (RePORT Database, CIRM, MRC, Wellcome Trust - UK)
- Stem Cell Patent Database (United States Patent and Trade Office, World Intellectual Property Organization)
- Stem Cell Clinical Trial Database (ClinicalTrials.gov, International Clinical Trials Registry Platform, European Union Clinical Trials Register )
- Stem Cell Scientific Publication Database (PubMed, Highwire Press, Google Scholar)
- Stem Cell Product Launch Announcements (Trade Journals, Google News)
- Stem Cell Industry Events (Google News, Google Alerts)
- Stem Cell Company News (SEC Filings, Investor Publications, Historic Performance)
- International Surveys (Electronically Distributed End-User Surveys)
- And More